NEMAURA MEDICAL, INC. (OTCMKTS:NMRD) Files An 8-K Other Events
Item 8.01. Other Events
announcing the completion of development of its second-generation
sugarBEAT non-invasive Continuous Glucose Monitoring skin-patch.
A copy of the press release is attached to this Current Report on
Form 8-K as Exhibit 99.1.
|
Exhibit No.
|
Description
|
|
99.1
|
Press Release, dated April 24, 2017
|
About NEMAURA MEDICAL, INC. (OTCMKTS:NMRD)
Nemaura Medical, Inc. is a holding company. The Company owns a diagnostic medical device company specializing in discovering, developing and commercializing specialty medical devices. The Company’s focus is on the development of a continuous glucose monitoring (CGM) device, which consists of a disposable patch containing a sensor, and a non-disposable miniature electronic watch with a re-chargeable power source. CGM through a non-invasive patch can enable early detection of subtle changes in blood glucose levels. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a CGM, named sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes, and may also be used to screen pre-diabetic patients. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. NEMAURA MEDICAL, INC. (OTCMKTS:NMRD) Recent Trading Information
NEMAURA MEDICAL, INC. (OTCMKTS:NMRD) closed its last trading session up +0.30 at 3.50 with 1,900 shares trading hands.
